ENTITY
Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (1877 HK)

220
Analysis
Health CareChina
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
24 Oct 2020 23:47

What HKEX Biotech "Step-Ups" Can Tell Us

This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...

Share
bearishEvergrande Auto
28 Sep 2020 16:36

Evergrande Auto (708 HK): EGM Ahead Of Star Market Listing

This week in StubWorld ... Three days after raising HK$4bn via a top-up placement, Evergrande Auto (708 HK) ("EA") also officially known...

Logo
291 Views
Share
17 Sep 2020 01:38

JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure

$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...

Logo
451 Views
Share
18 Sep 2019 15:37

Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China

We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...

Logo
542 Views
Share
11 Sep 2019 15:34

Shanghai Henlius Biotech IPO: Valuation Prescribed at Low-End

Shanghai Henlius Biotech (2696 HK) is a biopharmaceutical company and a non-wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) (2196...

Logo
526 Views
Share
x